Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Pier Francesco Ferrucci

ResearcherPublications, citations & collaboration network
249
Works
28,501
Citations
50
h-index
115
i10-index
How has Pier Francesco Ferrucci's publication output changed over time?
ScholarIQpublication output · 2015–2019

Output grew0% over the shown period — from 1 works in 2015 to 1 in 2019.

1
1
1
201520172019
What are the most-cited papers on Pier Francesco Ferrucci?
ScholarIQmost cited works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, Dirk Schadendorf, Reinhard Dummer, Michael Smylie, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Hill, John Wagstaff, Matteo S. Carlino, John B.A.G. Haanen, Michele Maio, Iván Márquez‐Rodas, Grant A. McArthur, Paolo A. Ascierto, Georgina V. Long, Margaret K. Callahan, Michael A. Postow, Kenneth F. Grossmann, Mario Sznol, Brigitte Dréno, Lars Bastholt, Arvin Yang, Linda M. Rollin, Christine E. Horak, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20158,191 CitationsOPEN ACCESS
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Piotr Rutkowski, Jean‐Jacques Grob, C. Lance Cowey, Christopher D. Lao, John Wagstaff, Dirk Schadendorf, Pier Francesco Ferrucci, Michael Smylie, Reinhard Dummer, Andrew Hill, David Hogg, John B.A.G. Haanen, Matteo S. Carlino, Oliver Bechter, Michele Maio, Iván Márquez‐Rodas, Massimo Guidoboni, Grant A. McArthur, Célèste Lebbé, Paolo A. Ascierto, Georgina V. Long, Jonathan Cebon, Jeffrey A. Sosman, Michael A. Postow, Margaret K. Callahan, Dana Walker, Linda Rollin, Rafia Bhore, F. Stephen Hodi, James Larkin
New England Journal of Medicine. 20175,410 CitationsOPEN ACCESS
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, Jean‐Jacques Grob, Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, David Hogg, Andrew F. Hill, Iván Márquez‐Rodas, John B.A.G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, Célèste Lebbé, Grant A. McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Lars Bastholt, Jasmine I. Rizzo, Ágnes Balogh, Andriy Moshyk, F. Stephen Hodi, Jedd D. Wolchok
New England Journal of Medicine. 20193,728 CitationsOPEN ACCESS
Related on ScholarIQ
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Paper
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Paper
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Paper
Immunotherapy and Immune Responses
Topic
Cancer Immunotherapy and Biomarkers
Topic
CAR-T cell therapy research
Topic
470M+ articles · free account